ATRC trades 4.4% above Wall Street's consensus target of $57.29.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ATRC achieves its forward estimates and maintains a stable P/E multiple of 560.9x. This scenario reflects the blended consensus of 19 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, AtriCure, Inc. (ATRC) has a Wall Street consensus price target of $57.29, based on estimates from 19 covering analysts. With the stock currently trading at $59.95, this represents a potential downside of -4.4%. The company has a market capitalization of $3.05B.
Analyst price targets range from a low of $50.00 to a high of $65.00, representing a 26% spread in expectations. The median target of $55.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 18 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ATRC trades at a trailing P/E of -249.8x and forward P/E of 560.9x. Analysts expect EPS to grow -50.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
 IRTCiRhythm Technologies, Inc. | $3.7B | $111.75 | $174.88 | +56.5% | Buy | — | 20 |
 BEATHeartBeam, Inc. | $22M | $0.39 | — | — | — | — | — |
 ABTAbbott Laboratories | $180.3B | $103.53 | $121.50 | +17.4% | Buy | 18.8x | 41 |
 MDTMedtronic plc | $114.7B | $89.30 | $98.00 | +9.7% | Buy | 14.9x | 51 |
 BSXBoston Scientific Corporation | $66.3B | $44.62 | $66.30 | +48.6% | Buy | 13.6x | 44 |
 JNJJohnson & Johnson | $648.0B | $269.17 | $286.93 | +6.6% | Buy | 23.4x | 40 |
 EWEdwards Lifesciences Corporation | $50.0B | $86.82 | $101.70 | +17.1% | Buy | 28.9x | 49 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 SYKStryker Corporation | $104.8B | $273.40 | $372.39 | +36.2% | Buy | 18.2x | 52 |
Quick answers to the most common questions about buying ATRC stock.
Wall Street's consensus price target for ATRC is $57.29, -4.4% from its current price of $59.955. The below-market target from 19 analysts suggests limited near-term appreciation.
ATRC has a consensus rating of "Buy" based on 19 Wall Street analysts. The rating breakdown is predominantly bullish, with 18 Buy/Strong Buy ratings. The consensus 12-month price target of $57.29 implies -4.4% downside from current levels.
At a forward P/E of 560.8513x, ATRC trades at a premium valuation. The consensus price target of $57.29 (-4.4% downside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $65 for ATRC, while the most conservative target is $50. The consensus of $57.29 represents the median expectation. These targets typically reflect 12-month expectations.
ATRC is well covered by analysts, with 19 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 18 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ATRC stock forecast based on 19 Wall Street analysts shows a consensus price target of $57.29, with estimates ranging from $50 (bear case) to $65 (bull case). The median consensus rating is "Buy".
ATRC trades at a forward P/E ratio of 560.9x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on ATRC, with 0 Sell ratings and a price target of $57.29 (-4.4% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ATRC analyst price targets range from $50 to $65, a 26% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $57.29 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.